Mayne Pharma Group

Mayne Pharma Group Net Margin

The Net Profit Margin of Mayne Pharma Group (MYX.AX) as of Oct 18, 2026 is 6.38 %. In the previous year, Net Profit Margin was -22.99 % — a change of -127.74% (higher).

Net Margin

6.38 %

YoY

-127.74%

Last updated:

Net Profit Margin of Mayne Pharma Group is 2026 6.38 % . Net Profit Margin of Mayne Pharma Group was 2025 -22.99 % . It decreases by -127.74% higher compared to the previous year.

Mayne Pharma Group's net margin stands at 6.4%, up from -179.0% several years earlier.

The Mayne Pharma Group Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-53.16 AUD
Jan 1, 2020
-20.30 AUD
Jan 1, 2021
-52.00 AUD
Jan 1, 2022
-179.00 AUD
Jan 1, 2023
63.87 AUD
Jan 1, 2024
-44.89 AUD
Jan 1, 2025
-22.99 AUD
Jan 1, 2026
6.38 AUD
The Mayne Pharma Group Net Margin history
YEARNet MarginYoY
6.38 %-127.74%
-22.99 %-48.78%
-44.89 %-170.28%
63.87 %-135.68%
-179.00 %+244.19%
-52.00 %+156.12%
-20.30 %-61.81%
-53.16 %+110.41%
-25.27 %-263.34%
15.47 %+10.67%
13.98 %+152.76%
5.53 %-63.07%
14.97 %-43,426.79%
-0.03 %-128.69%
0.12 %+249.89%
0.03 %-60.80%
0.09 %-102.43%
-3.62 %-14.51%
-4.23 %-67.50%
-13.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mayne Pharma Group Stock analysis

What does Mayne Pharma Group do? Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mayne Pharma Group stock

Net Profit Margin of Mayne Pharma Group is 6.38 % in 2026.

Net Profit Margin of Mayne Pharma Group changed from -22.99 % to 6.38 %, representing a -127.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Mayne Pharma Group since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Mayne Pharma Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Mayne Pharma Group

All Key Metrics — Mayne Pharma Group